Vertex’s IgA nephropathy drug halves a key kidney biomarker in Phase 3
TL;DR Summary
Vertex reported Phase 3 data showing its IgA nephropathy drug reduced a key kidney-disease biomarker by about 50%, in a three-way race with Otsuka and Vera Therapeutics and signaling potential multi-billion-dollar annual sales.
- Vertex says its drug successfully reduced marker of kidney disease in late-stage trial statnews.com
- Vertex races to FDA after phase 3 kidney disease data impress analysts Fierce Biotech
- Vertex's kidney disease drug meets main goal in late-stage trial AOL.com
- Vertex's $4.9B kidney disease bet hits key milestone The Business Journals
- Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy Business Wire
Reading Insights
Total Reads
0
Unique Readers
17
Time Saved
2 min
vs 3 min read
Condensed
92%
416 → 33 words
Want the full story? Read the original article
Read on statnews.com